Reports on HIV/AIDS: 1990

NOVEMBER 23, 1990, MMWR, Vol. 39, No. 46, pp. 829-831
References
1. George JR, Rayfield MA, Phillips S, et al. Efficacies of U.S. Food and Drug Administrationlicensed HIV-1-screening enzyme immunoassays for detecting antibodies to HIV-2. AIDS
1990;4:321-6.
2. Schumacher RT, Howard J, Ayres L, Pista A, Avillez F, Garrett P. Cross-reactivity of anti-HIV-2
positive serum in U.S. FDA licensed screening tests for anti-HIV-1 [Abstract]. VI International
Conference on AIDS. Vol 3. San Francisco, June 20-24, 1990:245.
3. World Health Organization. Recommendations for the interpretation of HIV-2 Western blot
results. Wkly Epidemiol Rec 1990;65:69-76.
4. Petersen LR, Dodd R, Dondero TJ. Methodologic approaches to surveillance of HIV infection
among blood donors. Public Health Rep 1990;105:153-7.
5. Busch MP, Petersen LR, Schable C, Perkins HA. Monitoring blood donors for HIV-2 infection
by testing anti-HIV-1 reactive sera. Transfusion 1990;30:184-7.
6. CDC. AIDS due to HIV-2 infection-New Jersey. MMWR 1988;37:33-5.
7. O'Brien TR, Schable CA, Polon C, et al. HIV-2 infections in the United States [Abstract]. VI
International Conference on AIDS. Vol 2. San Francisco, June 20-24, 1990:245.
8. Parkman PD. Use of Genetic Systems HIV-2 EIA [Memorandum to all registered blood
establishments]. Bethesda, Maryland: Food and Drug Administration, Center for Biologics
Evaluation and Research, 1990.
9. Parkman PD. Recommendations for the prevention of human immunodeficiency virus (HIV)
transmission by blood and blood products [Memorandum to all registered blood establishments]. Bethesda, Maryland: Food and Drug Administration, Center for Biologics Evaluation
and Research, 1990.

123